A lipid-modulating protein that exemplifies the value of human genetics for target validation has provided a fertile testing ground for new drug modalities including long-acting RNA interference drugs, vaccines against self-antigens, CRISPR therapeutics and small molecules that control ribosomal activity.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Comparative analysis of obesity-related cardiometabolic and renal biomarkers in human plasma and serum
Scientific Reports Open Access 28 October 2019
-
A genome-wide positioning systems network algorithm for in silico drug repurposing
Nature Communications Open Access 02 August 2019
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Mullard, A. Nine paths to PCSK9 inhibition. Nat Rev Drug Discov 16, 299–301 (2017). https://doi.org/10.1038/nrd.2017.83
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.83
This article is cited by
-
Widening the horizons of oligonucleotide drug platforms
Biopharma Dealmakers (2023)
-
Comprehensive characterization of protein–protein interactions perturbed by disease mutations
Nature Genetics (2021)
-
A genome-wide positioning systems network algorithm for in silico drug repurposing
Nature Communications (2019)
-
Comparative analysis of obesity-related cardiometabolic and renal biomarkers in human plasma and serum
Scientific Reports (2019)